The FDA sent warning letters to eight companies, including CVS and Walgreens, warning them against making or selling unapproved eye products.
ABCNews
In their letters, the FDA also said people using these unapproved eye products that claim to treat or cure certain conditions may cause delay or stoppage of treatments that are approved by the agency. The FDA told the companies they have 15 days to respond to the FDA in writing to address any steps they have taken to correct violations.
France Dernières Nouvelles, France Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
FDA issues warning letter to CVS, Walgreens and others for selling unapproved eye products By ReutersFDA issues warning letter to CVS, Walgreens and others for selling unapproved eye products
Lire la suite »
FDA warns CVS, Walgreens about marketing of unapproved eye productsThe U.S. Food and Drug Administration this week warned CVS Health Corp. Walgreens Boots Alliance Inc. and several smaller consumer products companies about...
Lire la suite »
FDA warns CVS, Walgreens, others about manufacturing unapproved eye productsThe FDA is warning companies about marketing unapproved eye products
Lire la suite »
FDA warns CVS, others against selling unapproved eye productsThe U.S. Food and Drug Administration on Tuesday warned eight companies, including pharmacy giants CVS Health Corp and Walgreens Boots Alliance , against manufacturing or marketing unapproved eye products.
Lire la suite »
US pharmacy chains gear up to administer updated COVID shotsDrugstore chains CVS Health and Walgreens Boots Alliance said on Wednesday that updated COVID-19 vaccines would be available at their stores as soon as this week.
Lire la suite »
Walgreens In Deal With Tech Firm Pearl Health To Enhance Work With Primary Care DoctorsWalgreens has partnered with the technology company Pearl Health to assist primary care doctors with software and services they need in the shift to value-based care.
Lire la suite »